Results 131 to 140 of about 218,171 (299)

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld   +9 more
wiley   +1 more source

Exploring the health benefits of gut microbiota metabolites on combating ulcerative colitis via network pharmacology, bioinformatics and molecular docking

open access: yesScientific Reports
Ulcerative colitis (UC) is a leading health challenge worldwide. The evidence of the benefits of gut microbiota metabolites for the treatment of ulcerative colitis is accumulating, but the underlying mechanism remains to be further elucidated. Hence, the
Weiguo Yao   +3 more
doaj   +1 more source

Building a Robust Investigator‐Initiated Platform: The I‐CARE Experience

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Investigator‐initiated studies that include information collected by patients are rising, but limited data is available on patient and investigator experience in this setting. The I‐CARE cohort included patients with inflammatory bowel disease (IBD) monthly collecting clinical information in 15 countries for up to 6 years.
Julien Kirchgesner   +906 more
wiley   +1 more source

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi   +100 more
wiley   +1 more source

Scintigraphy with 99mTc(V)-DMSA in monitoring patients with inflammatory bowel disease [PDF]

open access: yes, 2013
The clinical significance of pentavalent technetium-99m dimercaptosuccinic acid (99mTc(V)-DMSA) scintigraphy in diagnosing inflammatory bowel disease (IBD) has not yet been fully elucidated. The aim of this prospective paper was to study the above.
Abedi, J.   +7 more
core  

Financial Toxicity Associated with Biological Medicines: A Scoping Review

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka   +4 more
wiley   +1 more source

Gut‐microbiota‐brain Axis and post‐traumatic epilepsy

open access: yesEpilepsia Open, EarlyView.
Abstract There has been growing evidence that perturbations in gut‐microbiota‐brain axis (GMBA) are involved in mechanisms of chronic sequelae of traumatic brain injury (TBI). This review discusses the connection between GMBA and post‐traumatic epilepsy (PTE), the latter being a common outcome of TBI.
Andrey Mazarati
wiley   +1 more source

β-ionone prevents dextran sulfate sodium-induced ulcerative colitis and modulates gut microbiota in mice

open access: yesFood Innovation and Advances
β-ionone has various biological activities, such as anti-inflammatory, antimicrobial, and anticancer effects. The pathogenesis of ulcerative colitis is correlated with immune dysfunction, intestinal barrier damage, and gut microbiota imbalance.
Jingjing Fang   +5 more
doaj   +1 more source

Ulcerative Colitis [PDF]

open access: yesClinics in Colon and Rectal Surgery, 2004
openaire   +2 more sources

Beyond Gut Modulation: A Critical Review of the Therapeutic Potential, Safety, and Clinical Prospects of Natural Polysaccharides for IBD

open access: yesFood Safety and Health, EarlyView.
In this review, we critically summarized the application of natural polysaccharides (NPs) for the treatment of IBD. This approach combines, in a unique way (right), the basic structure–activity relationships of NPs from different origins (left) with their multipronged mode of action, which involves modulation of the gut microbiota and other ...
Felix Danso   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy